@ ( @ % ) patients in the placebo group reported adverse events ( four -LSB- @ % -RSB- severe and six -LSB- @ % -RSB- serious ) , as did @ ( @ % ) patients in the empagliflozin @ mg group ( eight -LSB- @ % -RSB- severe and eight -LSB- @ % -RSB- serious ) , @ ( @ % ) patients in the empagliflozin @ mg group ( seven -LSB- @ % -RSB- severe and five -LSB- @ % -RSB- serious ) , and @ ( @ % ) patients in the sitagliptin group ( five -LSB- @ % -RSB- severe and six -LSB- @ % -RSB- serious ) .